• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康犬单次及多次口服左乙拉西坦后的药代动力学

Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.

作者信息

Moore Sarah A, Muñana Karen R, Papich Mark G, Nettifee-Osborne Julie

机构信息

Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.

出版信息

Am J Vet Res. 2010 Mar;71(3):337-41. doi: 10.2460/ajvr.71.3.337.

DOI:10.2460/ajvr.71.3.337
PMID:20187836
Abstract

OBJECTIVE

To measure pharmacokinetics of levetiracetam (LEV) after single-dose oral administration in healthy dogs and determine whether pharmacokinetics changed after repeated oral dosing.

ANIMALS

6 healthy adult dogs.

PROCEDURES

Pharmacokinetics were calculated following administration of a single dose (mean, 21.7 mg/kg, PO; day 1) and after administration of the last dose following administration for 6 days (20.8 to 22.7 mg/kg, PO, q 8 h; days 2 to 7). Plasma LEV concentrations were determined by use of high-pressure liquid chromatography. Pharmacokinetic data were analyzed by use of a 1-compartment model with first-order absorption.

RESULTS

Peak concentration occurred 0.6 hours after administration of the first dose, with an absorption half-life of 0.06 hours. Minimal accumulation occurred over the 7 days, with only a slight increase in total area under the concentration-versus-time curve from 268.52 +/- 56.33 h x microg/mL (mean +/- SD) to 289.31 +/- 51.68 h x microg/mL after 7 days. Terminal half-life was 2.87 +/- 0.21 hours after the first dose and 3.59 +/- 0.82 hours after the last dose on day 7. Trough plasma concentrations were variable, depending on the time of day they were measured (morning trough concentration, 18.42 +/- 5.16 microg/mL; midday trough concentration, 12.57 +/- 4.34 microg/mL), suggesting a diurnal variation in drug excretion.

CONCLUSIONS AND CLINICAL RELEVANCE

Results indicated that the pharmacokinetics of LEV did not change appreciably after administration of multiple doses over 7 days. Administration of LEV at a dosage of 20 mg/kg, PO, every 8 hours to healthy dogs yielded plasma drug concentrations consistently within the therapeutic range established for LEV in humans.

摘要

目的

测定左乙拉西坦(LEV)在健康犬单次口服给药后的药代动力学,并确定多次口服给药后药代动力学是否发生变化。

动物

6只健康成年犬。

方法

在单次给药(平均21.7mg/kg,口服;第1天)后以及连续6天给药(20.8至22.7mg/kg,口服,每8小时一次;第2至7天)并给予最后一剂后计算药代动力学。血浆LEV浓度通过高压液相色谱法测定。药代动力学数据采用具有一级吸收的单室模型进行分析。

结果

首次给药后0.6小时出现峰值浓度,吸收半衰期为0.06小时。在7天内仅有最小程度的蓄积,浓度-时间曲线下总面积仅从268.52±56.33小时×微克/毫升(平均值±标准差)轻微增加至7天后的289.31±51.68小时×微克/毫升。首次给药后终末半衰期为2.87±0.21小时,第7天最后一剂给药后为3.59±0.82小时。谷血浆浓度存在差异,取决于测量时间(早晨谷浓度,18.42±5.16微克/毫升;中午谷浓度,12.57±4.34微克/毫升),提示药物排泄存在昼夜变化。

结论及临床意义

结果表明,在7天内多次给药后LEV的药代动力学没有明显变化。以20mg/kg的剂量每8小时口服一次LEV给健康犬,其血浆药物浓度始终在为人类建立的LEV治疗范围内。

相似文献

1
Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.健康犬单次及多次口服左乙拉西坦后的药代动力学
Am J Vet Res. 2010 Mar;71(3):337-41. doi: 10.2460/ajvr.71.3.337.
2
Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats.单剂量口服和静脉注射左乙拉西坦后在临床正常猫体内的药代动力学
Am J Vet Res. 2011 Sep;72(9):1247-52. doi: 10.2460/ajvr.72.9.1247.
3
Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.左乙拉西坦静脉输注相对于口服片剂的单剂量生物利用度,以及在健康受试者中左乙拉西坦静脉输注与安慰剂相比的多剂量药代动力学和耐受性。
Clin Ther. 2006 May;28(5):734-44. doi: 10.1016/j.clinthera.2006.05.004.
4
Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas.左乙拉西坦的口服吸收动力学:与食物或肠内营养配方混合的影响。
Clin Ther. 2005 May;27(5):594-8. doi: 10.1016/j.clinthera.2005.05.010.
5
Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.犬肌肉注射、静脉注射及口服左乙拉西坦:安全性与药代动力学
J Vet Pharmacol Ther. 2008 Jun;31(3):253-8. doi: 10.1111/j.1365-2885.2008.00948.x.
6
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.左乙拉西坦静脉输注:一项随机、安慰剂对照的安全性和药代动力学研究。
Epilepsia. 2006 Jul;47(7):1128-35. doi: 10.1111/j.1528-1167.2006.00586.x.
7
Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.左乙拉西坦:10%口服溶液(750毫克)与750毫克片剂的相对生物利用度和生物等效性
J Clin Pharmacol. 2003 Dec;43(12):1370-6. doi: 10.1177/0091270003258173.
8
Single- and multiple-dose pharmacokinetics of marbofloxacin after oral administration to rabbits.马波沙星对兔口服给药后的单剂量和多剂量药代动力学。
Am J Vet Res. 2009 Apr;70(4):522-6. doi: 10.2460/ajvr.70.4.522.
9
Tolerability and efficacy of oral loading of levetiracetam.左乙拉西坦口服负荷剂量的耐受性和疗效。
Neurology. 2008 May 27;70(22 Pt 2):2166-70. doi: 10.1212/01.wnl.0000313151.64005.c0.
10
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.一项单剂量、三周期、六序列交叉研究,比较了空腹条件下健康墨西哥志愿者中镁丙戊酸盐溶液、混悬液和肠溶片剂的生物利用度。
Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.

引用本文的文献

1
Dissolution Characteristics of Split and Crushed Levetiracetam Extended-Release Tablets in Comparison With Immediate-Release Formulation.左乙拉西坦缓释片分割和碾碎后的溶出特性与速释制剂的比较
J Vet Pharmacol Ther. 2025 May 12;48(4):340-3. doi: 10.1111/jvp.13517.
2
The Single-Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs.复方左乙拉西坦制剂在健康犬体内的单剂量药代动力学及其与市售制剂的生物等效性
J Vet Pharmacol Ther. 2025 Mar;48(2):67-75. doi: 10.1111/jvp.13490. Epub 2024 Nov 13.
3
Factors influencing serum concentrations of levetiracetam in dogs with epilepsy.
影响癫痫犬左乙拉西坦血清浓度的因素。
J Vet Intern Med. 2024 Jul-Aug;38(4):2249-2256. doi: 10.1111/jvim.17128. Epub 2024 Jun 18.
4
Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study.左乙拉西坦在患有慢性肾病的癫痫犬中的应用:一项回顾性研究。
Vet Sci. 2021 Nov 3;8(11):263. doi: 10.3390/vetsci8110263.
5
Seizures and epilepsy in cats.猫的癫痫发作与癫痫
Vet Med (Auckl). 2014 Jul 30;5:41-47. doi: 10.2147/VMRR.S62077. eCollection 2014.
6
Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats.对健康猫每日3次经皮给予左乙拉西坦后血清左乙拉西坦浓度。
J Vet Intern Med. 2019 Mar;33(2):827-830. doi: 10.1111/jvim.15412. Epub 2019 Jan 21.
7
Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide.癫痫犬单独服用、与苯巴比妥或唑尼沙胺联用时缓释左乙拉西坦的群体药代动力学。
J Vet Intern Med. 2018 Sep;32(5):1677-1683. doi: 10.1111/jvim.15298. Epub 2018 Sep 20.
8
Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats.健康猫单次口服缓释左乙拉西坦的药代动力学
J Vet Intern Med. 2018 Jan;32(1):348-351. doi: 10.1111/jvim.14863. Epub 2017 Nov 8.
9
Antiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogs.抗癫痫药物的耐受性和安全性——犬类不良反应的系统评价和荟萃分析
BMC Vet Res. 2016 May 21;12:79. doi: 10.1186/s12917-016-0703-y.
10
2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs.2015年美国兽医内科学会犬癫痫发作管理小动物共识声明。
J Vet Intern Med. 2016 Mar-Apr;30(2):477-90. doi: 10.1111/jvim.13841. Epub 2016 Feb 22.